Design Principles of Hydrogel-Mediated Ocular Gene Therapy and Optimization of In Vivo Release Kinetics
-
Physical barriers to ocular drug delivery and limits of bioavailability The eye possesses sophisticated anatomical defenses—including tear turnover, corneal and conjunctival barriers, and the retinal‑blood barrier (BRB)—that reduce the bioavailability of conventional eye‑drop formulations to less than 5%. Large nucleic‑acid‑based gene therapeutics such as DNA, RNA, and CRISPR‑Cas systems are especially vulnerable to degradation by the ocular microenvironment and nucleases, making delivery to target cells extremely challenging. To overcome these obstacles, three‑dimensional polymeric networks known as hydrogel carriers have emerged as a strategy to protect gene cassettes and provide sustained, localized release.
-
Smart stimuli‑responsive hydrogel transition mechanisms Next‑generation ocular hydrogels are molecularly engineered to undergo physical phase transitions in response to external cues.
- Temperature‑responsive hydrogels: Remain liquid at room temperature (20–22 °C) for easy injection, but rapidly gel at ocular surface or intra‑ocular temperatures (34–35 °C), thereby preventing loss due to blinking.
- Light‑ and pH‑responsive hydrogels: Detect specific wavelengths of light or the subtle acidic shifts characteristic of inflamed tissue, triggering reversible cross‑linking changes that enable on‑demand release of the gene cassette at the desired time and location.
- Covalent conjugation vs. physical loading: molecular distinctions in gene‑hydrogel integration strategies The method used to embed gene vectors within the hydrogel critically determines transfection efficiency.
- Physical loading: Entraps nucleic acids within the hydrogel mesh, yielding a rapid initial release but carrying a risk of burst release caused by swelling of the network.
- Covalent conjugation: Chemically links the surface of gene vectors or lipid nanoparticles (LNPs) to the polymer chains of the hydrogel. This architecture sterically blocks nuclease access, maximizes stability, and can be synchronized with polymer degradation to achieve zero‑order release kinetics.
- Why it matters: enabling reversible, long‑acting gene therapy from the anterior segment to the fundus This review and technology outlook are pivotal because they address the two major shortcomings of ocular gene therapy—repeated dosing risk and lack of durability—through materials engineering. A single injection capable of sustaining gene‑therapeutic release for months could dramatically improve adherence in patients with refractory posterior‑segment diseases such as age‑related macular degeneration (AMD) or diabetic retinopathy. Moreover, fine‑tuning the rheological properties of the carrier permits stable delivery of the cassette to deep retinal layers, positioning hydrogel platforms as a unique hardware shield that maximizes in‑vivo editing efficiency of next‑generation gene‑editing toolkits.
Hydrogel-mediated gene therapy has achieved significant progress in the field of ophthalmology in recent years. As three-dimensional polymeric networks with high water content, hydrogels exhibit excellent biocompatibility, localized targeting capability and sustained-release properties. These characteristics make them ideal carriers for nucleic acid-based drugs, including DNA, RNA and gene editing systems. They can significantly improve the therapeutic efficacy and delivery kinetics of ocular drug administration, demonstrating unique advantages in the special ocular environment. This review systematically examines the current state of hydrogel-based gene therapy research in ophthalmology. First, recent advances in gene therapy are summarized, and the involved gene types and technical strategies are categorized. Second, various categories of hydrogels are outlined, including photo-responsive, temperature-sensitive and pH-responsive hydrogels. Their key characteristics for ocular gene delivery are also summarized. Furthermore, this article focuses on analyzing the design strategies for hydrogel-mediated gene therapy. Key design considerations include gene encapsulation, stability control and release kinetics. In addition, various gene-hydrogel integration strategies are discussed, including covalent conjugation and physical loading methods. Their impacts on transfection efficiency and therapeutic outcomes are also analyzed. Additionally, cutting-edge applications of hydrogel-based gene therapy in treating ocular diseases are systematically introduced, covering both anterior segment and fundus diseases. Finally, the limitations and future development prospects of these gene therapy hydrogel systems in ophthalmic research are discussed.
This dataset systematizes an architecture guide that integrates biocompatible hydrogels with gene therapeutics to optimize intra‑ocular drug release kinetics. It contains physicochemical mapping information spanning anterior‑segment and posterior‑segment diseases, making it a high‑value foundational dataset for future AI‑driven drug‑release prediction algorithms and next‑generation delivery‑material screening platforms.